On Monday, Novo Nordisk A/S (NYSE:NVO) announced headline results from the REDEFINE 2 phase 3 trial in the global REDEFINE program. REDEFINE 2 is a 68-week efficacy and safety trial investigating once ...
Novo Nordisk has defended disappointing trial results for its much-hyped next generation obesity drug candidate CagriSema, insisting it will be an "important" weight loss treatment. "I'm very ...
LONDON/COPENHAGEN, March 10 (Reuters) - Novo Nordisk on Monday revealed weaker-than-expected data from a second late-stage trial of its obesity drug candidate CagriSema, knocking shares and stoking ...
Elaine’s stories explore the boom in new obesity treatments, new drug payment models, the ways companies are affected by FDA changes, and the emerging psychedelics drug sector. She co-writes The ...
On 5 June, at the 86th Scientific Sessions of the American Diabetes Association (ADA) in New Orleans, Louisiana, findings were presented on the effects of Novo Nordisk's CagriSema on appetite, eating ...
Data presented simultaneously at the American Diabetes Association’s® 85th Scientific Sessions, showed mean weight reduction in the highest range of efficacy observed with existing weight loss ...
Under the efficacy estimand, patients treated with CagriSema achieved a 23.0% weight loss compared with 25.5% in those treated with tirzepatide. Topline results were ...
In the REIMAGINE 1 trial, the most commonly reported adverse events (AEs) were gastrointestinal (GI)-related, occurring in 33/62 (53%) participants in the CagriSema 2.4 mg/2.4 mg group, 28/63 (44%) ...
Please provide your email address to receive an email when new articles are posted on . In patients with type 2 diabetes, CagriSema lowered HbA1c to a greater degree than semaglutide at 68 weeks.
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. CagriSema was tied to HbA1c and weight reductions in ...
Add Yahoo as a preferred source to see more of our stories on Google. Excitement is building around a new weight loss drug, CagriSema, which is expected to surpass the effects of popular drugs Ozempic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results